erdafitinib demonstrates efficacy in intermediate-risk nmibc with fgfr alterations
Published 1 year ago • 72 plays • Length 5:14Download video MP4
Download video MP3
Similar videos
-
1:27
thor-2 cohort 3 interim analysis: erdafitinib in intermediate-risk nmibc with fgfr3/2 alterations
-
2:15
tar-210 erdafitinib intravesical delivery system in non-muscle invasive bladder cancer
-
2:20
erdafitinib /- cetrelimab in muc patients with fgfr alterations
-
2:23
envision: ugn-102 and chemoablation for low-grade, intermediate-risk nmibc
-
4:28
very high risk non-muscle-invasive bladder cancer (nmibc) in the current landscape of nmibc
-
3:42
norse: erdafitinib cetrelimab in muc with fgfr alterations
-
4:51
expert video report on the management of patients with high-risk non-muscle invasive bladder cancer
-
1:27
erdafitinib and enfortumab vedotin in pretreated fgfr2/3-mutant bladder cancer
-
28:29
understanding bladder cancer carcinoma in-situ (cis)
-
26:20
management of non-muscle invasive bladder cancer
-
25:23
non muscle invasive bladder cancer | experts discuss: a breakdown of nmibc
-
2:12
erdafitinib: one more tool for bladder cancer
-
0:40
nadofaragene firadenovec shows durable responses in nmibc
-
1:49
blc2001: erdafitinib for the treatment of metastatic urothelial carcinoma
-
1:47
dr. sonpavde on the safety profile of erdafitinib in bladder cancer
-
2:20
the role of erdafitinib in treating patients with bladder cancer
-
2:31
an update on erdafitinib for metastatic/uresectable fgfr alteration urothelial carcinoma
-
0:55
targeted therapy option of erdafitinib in bladder cancer #oncology #cancer #2023
-
1:28
erdafitinib for bladder cancer: more to come following fda approval
-
1:51
dr. siefker-radtke on the treatment of fgfr-altered bladder cancer
-
4:59
cg0070 combined with pembro shows promising efficacy in patients with nmibc unresponsive to bcg
-
1:47
the future role of erdafitinib in advanced urothelial carcinoma